ABSTRACT
Eric Finzi, MD, PhD, assistant clinical professor of psychiatry at George Washington School of Medicine & Health Sciences, Department of Psychiatry and Behavioral Sciences and colleagues have found that Botulinum Toxin A has strong antidepressant properties for bipolar depression. The results showed that four of six patients with bipolar depression who were treated with Botox Cosmetic for glabellar frown lines (between the eyes) had a sustained remission of their depression. The study is published in the September 2018 issue of Journal of Psychiatric Research.
Click here for the complete article from the Journal of Psychiatric Research.